Эффективность интравитреального введения бевацизумаба при лечении рефрактерного диабетического макулярного отека

Objectives. To estimate both efficacy and safety of bevacizumab intravitreal injection in patients with refractory diabetic macular edema. Methods. Randomized trial of 160 eyes of 82 patients with refractory diabetic macular edema has been carried out. Patients in whom intravitreal injections of 1, 25 mg in 0, 05 ml of bevacizumab were done composed the main group (61 eyes). In the given group ophthalmological examinations were performed on the 2nd, 4th, 8th, 12th, 16th, 20th and 24th weeks of observation and further they were carried out every 3 months up to the end of the observation period. Control group of patients (99 eyes) were subjected to repeated sessions of focal laser coagulation with ophthalmological examinations before the procedure. Results. Clinical trials have determined that a new method of treatment reliably permits to decrease central thickness of the retina and to increase visual acuity in comparison with control group of patients Conclusions. Intravitreal injection of bevacizumab is an effective and safe method of patients with refractory diabetic macular edema treatment; it permits in short time to reduce the retina edema, to stabilize or to increase patients, visual acuity and it also contributes to regression of the retina neovascularization.